Oxford and AstraZeneca resume coronavirus vaccine trial

- Advertisement -

Oxford University announced Saturday it was resuming a trial for a coronavirus vaccine it is developing with pharmaceutical company AstraZeneca, a move that comes days after the study was suspended following a reported side-effect in a UK patient.

“The independent review process has concluded and following the recommendations of both the independent safety review committee and the U.K. regulator, the MHRA, the trials will recommence in the U.K.,’’ the university confirmed.

The vaccine being developed by Oxford and AstraZeneca is widely perceived to be one of the strongest contenders among the dozens of coronavirus vaccines in various stages of testing around the world.

READ  Russian coronavirus vaccine trials to be held in Saudi Arabia

The university said in large trials such as this “it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety.’’

It said globally some 18,000 people have received its vaccine so far. Volunteers from some of the worst affected countries _ Britain, Brazil, South Africa and the U.S. _ are taking part in the trial.

Brazil’s health regulator Anvisa on Saturday said it had approved the resumption of tests of the “Oxford vaccine’’ in the South American country after receiving official information from AstraZeneca.

Although Oxford would not disclose information about the patient’s illness due to participant confidentiality, an AstraZeneca spokesman said earlier this week that a woman had developed severe neurological symptoms that prompted the pause. Specifically, the woman is said to have developed symptoms consistent with transverse myelitis, a rare inflammation of the spinal cord.

READ  US Drugmaker's Vaccine Trial Shows Promising Early Results

The university insisted that it is “committed to the safety of our participants and the highest standards of conduct in our studies and will continue to monitor safety closely.’’

Pauses in drug trials are commonplace and the temporary hold led to a sharp fall in AstraZeneca’s share price following the announcement Tuesday.

Comments

- Advertisement -